Download PDF
Klin Monbl Augenheilkd 2022; 239(04): 531-533
DOI: 10.1055/a-1766-6623
Der interessante Fall

Long-Term Efficacy of Intravitreal Anti-VEGF Therapy for Choroidal Neovascularization in a Case of Fundus Flavimaculatus (FFM)

Langzeitige Effektivität der intravitrealen Anti-VEGF-Injektionstherapie chorioidaler Neovaskularisationen bei einem Patienten mit Fundus flavimaculatus (FFM)
Ioanna Zygoula
Dept. of Ophthalmology, Pallas Kliniken, Olten, Switzerland
,
Lars Hefner
Dept. of Ophthalmology, Pallas Kliniken, Olten, Switzerland
,
Heinrich Gerding
Dept. of Ophthalmology, Pallas Kliniken, Olten, Switzerland
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Background

Fundus flavimaculatus (FFM) is a subgroup of flecked retina syndrome, characterized by yellowish-white fishtail-like flecks of lipofuscin-like material, scattered diffusely throughout the fundus [1], [2]. A rare complication of FFM associated with severe vision loss is choroidal neovascularization (CNV) [3]. So far, various therapies, mainly based on photodynamic therapy (PDT), have been applied to treat this threatening condition. However, only short-term results have been published presenting varying visual outcomes [4], [5]. In this case report, the successful long-term outcome of intravitreal administration of ranibizumab (Lucentis) in a middle-aged male is described.



Publication History

Received: 25 September 2021

Accepted: 06 February 2022

Article published online:
26 April 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Franceschetti A, François J. [Fundus flavimaculatus]. Arch Ophtalmol Rev Gen Ophtalmol 1965; 25: 505-530
    PubMedGoogle Scholar
  • 2 Krill AE, Klien BA. Flecked retina syndrome. Arch Ophthalmol 1965; 74: 496-508
    CrossrefPubMedGoogle Scholar
  • 3 Klein R, Lewis RA, Meyers SM. et al. Subretinal neovascularization associated with fundus flavimaculatus. Arch Ophthalmol 1978; 96: 2054-2057
    CrossrefPubMedGoogle Scholar
  • 4 Souied EH, Pawlak D, Algan M. et al. Photodynamic therapy for choroidal neovascularization on late-onset fundus flavimaculatus. Am J Ophthalmol 2005; 140: 312-314
    CrossrefPubMedGoogle Scholar
  • 5 Valmaggia C, Niederberger H, Helbig H. Photodynamic therapy for choroidal neovascularization in fundus flavimaculatus. Retina 2002; 22: 111-113
    CrossrefPubMedGoogle Scholar
  • 6 Pawlak D, Souied E, Mimoun G. et al. [Fundus flavimaculatus and choroidal neovascularization]. J Fr Ophtalmol 2006; 29: 188-194
    CrossrefPubMedGoogle Scholar
  • 7 Tejerina AN, García-Pous M, Pozos EP. et al. Ranibizumab for choroidal neovascularization in fundus flavimaculatus. Retin Cases Brief Rep 2008; 2: 250-252
    CrossrefPubMedGoogle Scholar
  • 8 Saatci AO, Ayhan Z, Yüksel B. et al. Intravitreal aflibercept injection and photodynamic treatment of a patient with unilateral subretinal neovascular membrane associated with fundus flavimaculatus. Case Rep Ophthalmol Med 2015; 2015: 748420
    PubMedGoogle Scholar
  • 9 Braun B, Schneider U, Hasler P. et al. Combination therapy of PDT and triamcinolone in CNV associated with fundus flavimaculatus. Klin Monbl Augenheilkd 2007; 224: 353-355
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Koh V, Naing T, Chee C. Fundus flavimaculatus and choroidal neovascularization in a young patient with normal electroretinography: case report. Can J Ophthalmol 2012; 47: e3-e5
    CrossrefPubMedGoogle Scholar
  • 11 Quijano C, Querques G, Massamba N. et al. Type 3 choroidal neovascularization associated with fundus flavimaculatus. Ophthalmic Res 2009; 42: 152-154
    CrossrefPubMedGoogle Scholar